Compugen Presents Experimental Results for Three G-Protein Coupled Receptor Ligands
News May 27, 2008
Speaking before the 5th International Conference on Relaxin and Related Peptides in Maui, Hawaii, Dr. Ronen Shemesh of Compugen Ltd. has presented experimental results for three Compugen discovered Relaxin related molecules that could have therapeutic activity in various clinical indications, including labor complications, infertility, inflammation, congestive heart failure and fibrotic diseases.
The three novel peptides, CGEN-25009, 25010 and 25011, were predicted in silico through the use of Compugen’s GPCR Peptide Discovery Platform and were then shown to activate the GPCRs LGR7 (RXFP1) and LGR8 (RXFP2). These receptors are known to be activated by Relaxin and Insulin-like 3 (INSL3), respectively.
CGEN-25009, 25010 and 25011 are short and linear peptides derived through the use of the GPCR platform novel cleavage sites predictor from a precursor protein for which there was no known function.
In his presentation, Dr. Shemesh, project manager for the GPCR platform, summarized recently obtained results from a series of further experiments with the three peptides – such as cAMP measurements and downstream changes measured by cell impedance.
In these experiments, the activation of the GPCRs LGR7 and LGR8 was further confirmed and additional information obtained regarding the activity of these novel molecules. By activation of these receptors, these peptides could potentially have a therapeutic effect in a large number of key pathophysiological conditions. A provisional patent application covering the peptides has been filed by Compugen.
“Our GPCR Peptide Discovery Platform relies on a series of sequential computational biology predictive models and machine learning capabilities,” stated Dr. Shemesh.
“Therefore – and particularly in view of both the critical role of GPCR receptors in the pharmaceutical world and the difficulty in finding novel ligands through traditional experimental methods -- it is extremely rewarding for the project team to see the continuing validation of the platform’s exceptional efficiency and accuracy,” Dr. Shemesh concluded.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.